MAPT and dementia: To fully understand how the CU-D construct aligns with dementia endpoints and the new NIA-AA A/T(N) framework (Jack et al., 2018), a larger sample of participants would be beneficial to see if amyloid and tau patterns persist, as would examining how CU-S, CU-D and MCI groups differ on additional biomarkers (e.g., neurodegeneration and vascular biomarkers).